Jim Cramer notes
DaVita's substantial buybacks but maintains a cautious stance. DaVita faces a potential narrative shift due to falling patient volumes. While
Aristeia Capital, Amundi, Bayforest Capital, and the
Royal Bank of Canada have significantly increased their stake in DaVita, the
Bank of America predicts a downturn in stock price.
DaVita plans to expand its $8 billion buyback program; however, the company also reported a
ransomware attack affecting 2.7 million people. Despite market gains, DaVita stock has experienced some declines. Quarters 2 and 1 of 2025 show DaVita navigating challenges with resilience; the firm also beats its earnings and revenue estimates. Its aggressive buybacks continue despite rising debt costs. It posted better-than-expected Q4 sales, but its stock dips.
Berkshire Hathaway divests some DaVita shares, reducing its stake to 45%. DaVita's stock underperforms the S&P 500. In addition, DaVita announces an offering of $750 million Senior Notes while undergoing contraction and facing incremental earnings hurdles. DaVita's earnings have not entirely convinced investors. However, the company has a focus on improving kidney care, showcasing progress towards its ESG goals, and reveals expansion plans globally.
Davita DVA News Analytics from Wed, 29 Jan 2025 08:00:00 GMT to Sat, 13 Sep 2025 19:17:28 GMT -
Rating -1
- Innovation 2
- Information 8
- Rumor -5
